Edition:
United Kingdom

Oramed Pharmaceuticals Inc (ORMP.OQ)

ORMP.OQ on NASDAQ Stock Exchange Capital Market

7.40USD
23 Feb 2018
Change (% chg)

$0.03 (+0.41%)
Prev Close
$7.37
Open
$7.36
Day's High
$7.42
Day's Low
$7.36
Volume
1,171
Avg. Vol
8,922
52-wk High
$11.34
52-wk Low
$5.85

Latest Key Developments (Source: Significant Developments)

Oramed receives approval for clinical study to treat NASH
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Oramed Pharmaceuticals Inc :Oramed receives regulatory approval to conduct clinical study for treatment of NASH with its oral insulin capsule.Israel's ministry of health granted company approval to initiate exploratory clinical study of ORMD-0801 in patients with NASH​.Proposed study will assess effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH​.Says ‍plans on initiating study in coming month​.  Full Article

Oramed Pharmaceuticals unit enters into service agreement with XERTECS GmbH
Thursday, 16 Jun 2016 

Oramed Pharmaceuticals Inc : On June 13, 2016, Oramed Ltd entered into a service agreement with XERTECS GmbH .As consideration for XERTECS services, subsidiary will pay XERTECS a total amount of up to EUR 2.36 million.  Full Article

BRIEF-Oramed Pharmaceuticals' Unit Enters Clinical Research Organization Services Agreement With Integrium

* SAYS ON FEB 14, A UNIT ENTERED CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT WITH INTEGRIUM EFFECTIVE AS OF NOV 1, 2017‍​